Helus Pharma sent out an invitation on Sunday afternoon. It says the company will present topline results from its Phase 3 APPROACH study of HLP003, an adjunctive treatment in major depressive disorder, on November 16, 2026.
That is today, and $HELP is +12.51% before the bell.
Read the notice for what it contains. A date. A drug name. A reminder that HLP003 has FDA Breakthrough Therapy Designation, which it already held when the notice went out. What it does not contain is a number from the study, and no later release is in the feed.
So the morning's buyers are paying up for the one piece of a Phase 3 that cannot miss its endpoint: the calendar entry.
For contrast on the same tape: #DRTS is +13.60% with numbers in the release. Interim data from its recurrent glioblastoma trial, eight treated patients all alive at a 6.9-month median follow-up, a 100% objective response rate in the six evaluable. Small and interim, but there is something there to argue with. A calendar entry can't be argued with at all.